Eli Lilly Shares Plunge 10% After Data for Experimental Oral Weight-Loss Drug
Lilly's Oral GLP-1, Orforglipron, Delivers Weight Loss of up to an Average of 27.3 Lbs in First of Two Pivotal Phase 3 Trials in Adults With Obesity
Eli Lilly Attain-1 Trial Shows Orforglipron's Efficacy and Safety at 72 Weeks
Eli Lilly to Submit Orforglipron for Regulatory Review by Year-End
Eli Lilly Orforglipron's Safety Profile Consistent With GLP-1 Agonists